Journal of Applied Physiology Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


J Appl Physiol (April 30, 2009). doi:10.1152/japplphysiol.00183.2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
107/1/217    most recent
00183.2009v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Golder, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Golder, F. J.
Submitted on February 17, 2009
Revised on April 14, 2009
Accepted on April 30, 2009

Spinal NMDA receptor activation is necessary for de novo, but not the maintenance of, A2a receptor-mediated phrenic motor facilitation

Francis J. Golder1*

1 University of Pennsylvania

* To whom correspondence should be addressed. E-mail: golderf{at}vet.upenn.edu.

Adenosine 2a (A2a) receptor agonists elicit persistent increases in phrenic nerve activity by transactivating the neurotrophin receptor, TrkB, near phrenic motoneurons. Our working model proposes that A2a receptor-mediated TrkB receptor activation strengthens glutamatergic synapses onto phrenic motoneurons. Activation of glutamate NMDA receptors has been implicated in other models of phrenic motor plasticity. Thus, we hypothesized that NMDA receptor activation also would contribute to A2a receptor-mediated phrenic motor facilitation. Adult male Sprague Dawley rats were anesthetized with urethane, mechanically ventilated, neuromuscularly paralyzed, and bilaterally vagotomized. The A2a receptor agonist, CGS-21680, and the NMDA receptor-channel blocker, MK-801, were administered intrathecally over the C4 spinal segment. Phrenic nerve activity was recorded before, during, and after drug administration. MK-801 (concentration range 0.1, 1.0, 10.0, and 100 µM) was administered 30 min before CGS-21680 (50 µM). MK-801 dose-dependently blocked A2a receptor-mediated phrenic motor facilitation. When administered at 60 min post-CGS-21680, MK-801 prevented further increases in phrenic nerve activity compared to the CGS-21680 alone (CGS-21680 alone at 120 min: 114 ± 19 %, CGS-21680 and MK-801 at 60 min post-CGS-21680: 61 ± 11 %, above baseline, p<0.05), but did not return phrenic motor output to baseline values. Our data suggest that NMDA receptor activation is necessary for de novo A2a receptor-mediated phrenic motor facilitation and that the maintenance of pre-existing phrenic motor facilitation does not involve NMDA receptor-dependent mechanisms.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1948 by the American Physiological Society.